Literature DB >> 9493684

Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies.

A Sauty1, T Rochat, O D Schoch, J Hamacher, A M Kurt, J M Dayer, L P Nicod.   

Abstract

Interstitial lung disease (ILD) is a complication of polymyositis (PM) and dermatomyositis (DM). It often manifests itself in association with myositis-specific antisynthetase autoantibodies, among which anti-Jo-1 antibodies are the most commonly encountered. In contrast, ILD associated with anti-Jo-1 antibodies without muscle involvement is rare and not well characterized. We report four patients presenting with ILD associated with anti-Jo-1 antibodies. Histological findings of transbronchial biopsies disclosed a pattern consistent with nonspecific interstitial pneumonitis, a CD8+ lymphocytosis was found in bronchoalveolar lavage. Only one of these patients developed an "antisynthetase syndrome" with PM, after nearly 2 yrs of severe ILD. The clinical conditions of all four cases showed stabilization or improvement when cyclosporine was added to their immunosuppressive treatment. These cases confirm that a CD8+ lymphocytic interstitial lung disease may be the first, and sole manifestation of autoimmune disease associated with anti-Jo-1 antibodies. Furthermore, they suggest that this form of interstitial lung disease apparently has a poor response to steroids and cytotoxic drugs, but may respond to moderate doses of cyclosporine and azathioprine in addition to low doses of steroids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9493684     DOI: 10.1183/09031936.97.10122907

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

1.  Interstitial lung disease in a patient with antisynthetase syndrome and no myositis.

Authors:  Sotiris C Plastiras; Fotini C Soliotis; Panayiotis Vlachoyiannopoulos; George E Tzelepis
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

Review 2.  Myositis-related interstitial lung disease and antisynthetase syndrome.

Authors:  Joshua Solomon; Jeffrey J Swigris; Kevin K Brown
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

Review 3.  Recognition and treatment of idiopathic pulmonary fibrosis.

Authors:  L P Nicod
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 4.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  Armin Schnabel; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

5.  Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis.

Authors:  Li Zhang; Xiao-Hong Fu; Yong Yu; Ruo-Hong Shui; Chun Li; Hai-Ying Zeng; Yu-Lei Qiao; Li-Yan Ni; Qiang Wang
Journal:  Lab Invest       Date:  2014-11-10       Impact factor: 5.662

6.  Antisynthetase syndrome (ASS) presenting as acute respiratory distress syndrome (ARDS) in a patient without myositis features.

Authors:  Venkat Kiran Kanchustambham; Swetha Saladi; Sarah Mahmoudassaf; Setu Patolia
Journal:  BMJ Case Rep       Date:  2016-12-09

7.  Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis.

Authors:  Irina G Luzina; Virginia Lockatell; Sang W Hyun; Pavel Kopach; Phillip H Kang; Zahid Noor; Anguo Liu; Erik P Lillehoj; Chunsik Lee; Alba Miranda-Ribera; Nevins W Todd; Simeon E Goldblum; Sergei P Atamas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-03-18       Impact factor: 5.464

8.  The clinical phenotype of patients positive for antibodies to myositis and myositis-related disorders.

Authors:  S G Gofrit; H Yonath; M Lidar; Y Shoenfeld; S Kivity
Journal:  Clin Rheumatol       Date:  2018-02-16       Impact factor: 2.980

Review 9.  Pharmacogenetics and interstitial lung disease.

Authors:  Justin M Oldham; Imre Noth; Fernando J Martinez
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

Review 10.  Pulmonary complications of inflammatory myopathy.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.